# A Follow-up Study to Evaluate the Efficacy and Safety of ALLO-ASC-DFU in ALLO-ASC-EB-101 Clinical Trial

> **NCT03183934** · — · COMPLETED · sponsor: **Anterogen Co., Ltd.** · enrollment: 2 (actual)

## Conditions studied

- Dystrophic Epidermolysis Bullosa

## Interventions

- **BIOLOGICAL:** ALLO-ASC-DFU

## Key facts

- **NCT ID:** NCT03183934
- **Lead sponsor:** Anterogen Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-08
- **Primary completion:** 2018-04-20
- **Final completion:** 2023-04-30
- **Target enrollment:** 2 (ACTUAL)
- **Last updated:** 2023-08-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03183934

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03183934, "A Follow-up Study to Evaluate the Efficacy and Safety of ALLO-ASC-DFU in ALLO-ASC-EB-101 Clinical Trial". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03183934. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*